LURBINECTEDIN en Combinación con PEMBROLIZUMAB Para SCLC . El Ensayo Clínico LUPER DE FASE I-II Con 28 Pacientes Podría Concluir a Principios 2024 ... De Salir Bien Lógicamente Empezarán a Preparar la Definitiva Fase III Que Podría Empezar a Finales 2024 ... y Concluir entre Finales 2027 Inicios 2028 .


Study Type  :Interventional  (Clinical Trial)
Estimated Enrollment  :28 participants
Allocation:N/A
Intervention Model:Single Group Assignment
Intervention Model Description:Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer
Masking:None (Open Label)
Primary Purpose:Treatment
Official Title:Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Pembrolizumab in Patients With Relapsed Small Cell Lung Cancer
Actual Study Start Date  :September 21, 2020
Estimated Primary Completion Date  :October 31, 2023
Estimated Study Completion Date  :January 31, 2024